Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07486362 · ClinicalTrials.gov registry record
Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge
A clinical trial of Bacteremia, sponsored by Methodist Health System.
- Recruiting
- Registry status
- 126
- Enrollment target
- 1
- Study location
NCT07486362 is a study of Bacteremia that is actively recruiting participants, run by Methodist Health System. The registered enrollment target is 126 participants, below the 7,565-participant average among 11 other Bacteremia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07486362, a study of Bacteremia, is actively recruiting participants, sponsored by Methodist Health System.
- RECRUITING
- Registry status
- 126 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients are commonly discharged from the Emergency Department(ED) with pending blood culture results. Blood cultures can take up to 48 hours to become positive which is why it is important to notify patients with true positive cultures as soon as possible. Delay in notification can lead to other serious complications such as sepsis, septic shock, and death. The American College of Emergency Physicians states pharmacists serve a critical role in ensuring efficient, safe, and effective medication use in the ED and advocates for health systems to support dedicated roles for pharmacists within the ED. Pharmacists help to decrease the workload on the healthcare team, especially in the ED where there is high volume and acuity.Emergency medicine pharmacist (EMP) play a significant role in the optimization of therapy, medication safety, and reducing costs. There is strong evidence for the positive impact EMPs have on microbiological culture review. Overall, pharmacist review of late cultures results in higher rates of appropriate antimicrobial therapy and decreased missed interventions.These prior studies focused on the review of microbiological tests, including sexually transmitted infections, urine, and wound cultures; however, there was limited data to support the role of pharmacists evaluating late blood culture results.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
Texas
- Clinical Research Institute Methodist Health System - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2024-01-31 |
| Est. Completion | 2028-01-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07486362
The ClinicalTrials.gov registry entry for NCT07486362 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,565-participant average among 11 other Bacteremia trials with a reported enrollment target (98% lower). The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bacteremia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT07486362 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT07486362 about?
NCT07486362 is a clinical study titled "Evaluation of Emergency Medicine Pharmacist Impact on Blood Culture Review Following Emergency Department Discharge". Patients are commonly discharged from the Emergency Department(ED) with pending blood culture results. Blood cultures can take up to 48 hours to become positive which is why it is important to notify patients with true positive cultures as soon as possible. Delay in notification can lead to other se...
What is the current status of trial NCT07486362?
This trial is currently recruiting. The enrollment target is 126 participants. The study started on 2024-01-31. Estimated completion is 2028-01-31.
What conditions does trial NCT07486362 study?
This clinical trial studies the following conditions: Bacteremia.
What interventions are being tested in trial NCT07486362?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT07486362?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07486362 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacteremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reducing Risk for Infective Endocarditis
RECRUITING · NA
-
Monocyte Distribution Width (MDW) in the General Population of Emergency Department Patients With and Without Bacteremia
ACTIVE NOT RECRUITING
-
Antibiotic Administration and Blood Culture Positivity in Severe Sepsis and Septic Shock
COMPLETED
-
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness
COMPLETED · NA
-
Multicenter Blood Culture Quality Improvement
COMPLETED · NA
-
Comparison of Infection Rates Among Patients Using Two Catheter Access Devices
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.